alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › move

move

3 studies tagged move, dated 2010-06-01 to 2023-10-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion 2023-10-09
  2. Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward 2020-01-01
  3. Statins and neuroprotection: a prescription to move the field forward 2010-06-01

Studies

3 studies carry this tag.

Date range

2010 to 2023

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Annals of the New York Academy of Sciences 1
  • Neurology and therapy 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Neurology and therapy 2023-10-09 Drug development

    Passive immunotherapy in AD is largely dominated by anti-amyloid antibodies, which are more numerous and more advanced in the pipeline.

  2. Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-01-01 Brain scans and imaging

    The last decade has seen a substantial increase in research focused on the identification, development, and validation of diagnostic and prognostic retinal biomarkers for Alzheimer's disease (AD).

  3. Statins and neuroprotection: a prescription to move the field forward

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Annals of the New York Academy of Sciences 2010-06-01 Drug development

    There is growing interest in the use of statins, HMG-CoA reductase inhibitors, for treating specific neurodegenerative diseases (e.g., cerebrovascular disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis) and possibly traumatic brain injury.

All topic tags with their study counts